
Ollin Biosciences Secures $330 Million for Phase 3 Retina Drug Trials
Ollin Biosciences has raised $330 million in an oversubscribed Series B financing round, backed by a syndicate of top-tier healthcare investors. The capital will fund global Phase 3 clinical trials for IBI324, a bispecific antibody targeting diabetic macular edema and wet age-related macular degeneration, scheduled to begin in late 2026.






















